GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Other Current Receivables

INKT (MiNK Therapeutics) Other Current Receivables : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Other Current Receivables?

MiNK Therapeutics's Other Current Receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.


MiNK Therapeutics Other Current Receivables Historical Data

The historical data trend for MiNK Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Other Current Receivables Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Receivables
Get a 7-Day Free Trial 0.02 - - - -

MiNK Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MiNK Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


MiNK Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010